Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer

Oncotarget

Volumn 2, Issue 7, 2011, Pages 525-526

  Marcus, Assaf ^a   Eshhar, Zelig ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; FINGOLIMOD; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EDITORIAL; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LOW ENERGY RADIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MELANOMA; NEUROBLASTOMA; T LYMPHOCYTE; TREATMENT OUTCOME; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; CELL MOTION; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE TRANSFUSION; METHODOLOGY; NEOPLASM;

CELL MOVEMENT; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; NEOPLASMS; RECEPTOR, ERBB-2; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856657044     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.300     Document Type: Editorial

References (7)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8:299-308.
2. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virusspecific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14:1264-1270.
3. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigenspecific activation. Blood. 2005; 105:3087-3093.
4. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004; 114:1774-1781.
5. Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood.
6. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427:355-360.
7. Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. Curr Opin Mol Ther. 12:55-63.